<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538225</url>
  </required_header>
  <id_info>
    <org_study_id>M/SATIVX/01</org_study_id>
    <secondary_id>2011-002258-30</secondary_id>
    <nct_id>NCT01538225</nct_id>
  </id_info>
  <brief_title>Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity</brief_title>
  <acronym>NS-MSS</acronym>
  <official_title>Neurophysiologic Study on Effects of Sativex® on Spasticity in Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate&#xD;
      cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with&#xD;
      secondary or primary progressive Multiple Sclerosis (MS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H/M reflex ratio</measure>
    <time_frame>week 0, 4</time_frame>
    <description>To evaluate differences in the H/M ratio scores within subjects affected by progressive MS at baseline and week 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurophysiology ·H/M ratio ·Transcranial Magnetic Stimulation a) MEP Motor threshold, upper limb b) MEPs amplitudes c) Intracortical facilitation/inhibition (ICI/ICF), upper limb</measure>
    <time_frame>week 0, 4, 6 and 10</time_frame>
    <description>Neurophysiology&#xD;
H/M ratio: To evaluate differences in the H/M ratio scores within subjects affected by progressive MS at weeks 6 and 10&#xD;
Transcranial Magnetic Stimulation&#xD;
Motor threshold to obtain MEPs to the upper limb (time 0-4; 6-10 weeks);&#xD;
MEPs amplitudes at 15% above motor threshold, measured as MEP/M ratio to APB (abductor pollicis brevis) and abductor of hallucis, in which M is the compound muscle potential in response to peripheral stimulation (time 0-4; 6-10 weeks);&#xD;
Intracortical facilitation/inhibition (ICI/ICF) to the upper limb (time 0-4; 6-10 weeks);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events recording</measure>
    <time_frame>week 0, 4, 6 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity: ·0-10 11-point numerical spasticity rating scale (NRS) ·Mean modified Ashworth scale (MAS)</measure>
    <time_frame>week 0, 4, 6, 10</time_frame>
    <description>Mean spasticity score recorded using a 0-10 11-point numerical spasticity rating scale (NRS) at baseline (pre-treatment) and week 4, 6 and 10&#xD;
· Mean modified Ashworth (MAS) score at baseline (pre-treatment), week 4, 6, 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function: ·Timed 25 feet and 10 meters walk ·Hand dexterity measured with 9-HPT</measure>
    <time_frame>week 0, 4, 6, 10</time_frame>
    <description>Function:&#xD;
Mean Timed 25 feet and 10 meters walk recorded at baseline (pre-treatment) and week 4, 6, 10&#xD;
Mean Hand dexterity measured with 9-HPT recorded at baseline (pre-treatment) and week 4, 6, 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other MS Symptoms: ·Sleep Quality NRS ·Pain NRS and Spasm frequency ·Fatigue Severity Scale (FSS)</measure>
    <time_frame>week 0, 4, 6, 10</time_frame>
    <description>Other MS Symptoms:&#xD;
Mean Sleep Quality NRS recorded at baseline (pre-treatment) and week 4, 6, 10&#xD;
Pain NRS and Spasm frequency recorded at baseline (pre-treatment) and week 4, 6, 10&#xD;
Fatigue measured with the Fatigue Severity Scale (FSS) recorded at baseline (pre-treatment) and week 4, 6, 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>first sativex, second placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>first placebo, second sativex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex®</intervention_name>
    <description>THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.&#xD;
Duration: 2 weeks</description>
    <arm_group_label>first placebo, second sativex</arm_group_label>
    <arm_group_label>first sativex, second placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo&#xD;
Same frequency and dosage form as Sativex.&#xD;
Duration: 2 weeks</description>
    <arm_group_label>first placebo, second sativex</arm_group_label>
    <arm_group_label>first sativex, second placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or above&#xD;
&#xD;
          -  Willing and able to comply with the protocol for the duration of the study&#xD;
&#xD;
          -  Diagnosis of Secondary-Progressive or Primary-Progressive MS from at least 12 months&#xD;
&#xD;
          -  Relapse free from at least 3 months before screening visit&#xD;
&#xD;
          -  Lower limb spasticity&#xD;
&#xD;
          -  EDSS from &gt; 3.0 and &lt; 6.5&#xD;
&#xD;
          -  Moderate to severe spasticity due to MS from at least 6 months and with stable drug&#xD;
             treatment not able to relieve symptoms as a whole, deserving a specific add-on&#xD;
             treatment&#xD;
&#xD;
          -  Immunomodulatory or immunosuppressant therapies not modified during the study and 6&#xD;
             months before starting the study&#xD;
&#xD;
          -  Stable doses of anti-spasticity agents from at least 2 months prior to screening visit&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concomitant disease that may cause spasticity or that could interfere with&#xD;
             subject's spasticity&#xD;
&#xD;
          -  Botulinum Toxin injection for spasticity in the 4 months prior to screening visit&#xD;
&#xD;
          -  Any known or suspected history of psychotic illness, alcohol or substance abuse,&#xD;
             epilepsy, hypersensitivity to cannabinoids&#xD;
&#xD;
          -  Significant cardiac, renal or hepatic disease&#xD;
&#xD;
          -  Female subjects of child bearing potentials and male subjects whose partner is child&#xD;
             bearing potential, unless willing to ensure that they or their partner use&#xD;
             contraception during the study&#xD;
&#xD;
          -  Female subjects who is pregnant lactating or planning pregnancy during the course of&#xD;
             the study and for three months thereafter&#xD;
&#xD;
          -  Sativex® SmPC contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giancarlo Comi, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Experimental Neurology (Milan, Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Experimental Neurology</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spasticity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nabiximols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

